Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy
x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and cetuximab together with
radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and
cetuximab together with radiation therapy works in treating patients with HIV and stage I,
stage II, or stage III anal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation